

## **Product datasheet for SR306579**

### OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

## **SPATA2 Human siRNA Oligo Duplex (Locus ID 9825)**

#### **Product data:**

**Product Type:** siRNA Oligo Duplexes

Purity: HPLC purified

**Quality Control:** Tested by ESI-MS

Sequences: Available with shipment

**Stability:** One year from date of shipment when stored at -20°C.

# of transfections: Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final

conc. 10 nM).

**Note:** Single siRNA duplex (10nmol) can be ordered.

**RefSeq:** <u>NM 001135773</u>, <u>NM 006038</u>, <u>N62318</u>

UniProt ID: Q9UM82

**Synonyms:** PD1; PPP1R145; tamo

Components: SPATA2 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 9825)

Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol

Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml

**Summary:** Bridging factor that mediates the recruitment of CYLD to the LUBAC complex, thereby

regulating TNF-alpha-induced necroptosis (PubMed:27307491, PubMed:27458237,

PubMed:27545878, PubMed:27591049). Acts as a direct binding intermediate that bridges RNF31/HOIP, the catalytic subunit of the LUBAC complex, and the deubiquitinase (CYLD), thereby recruiting CYLD to the TNF-R1 signaling complex (TNF-RSC) (PubMed:27458237, PubMed:27545878, PubMed:27591049). Required to activate the 'Met-1'- (linear) and 'Lys-63'-linked deubiquitinase activities of CYLD (PubMed:27458237, PubMed:27591049). Controls the

kinase activity of RIPK1 and TNF-alpha-induced necroptosis by promoting 'Met-1'-linked

deubiquitination of RIPK1 by CYLD (By similarity).[UniProtKB/Swiss-Prot Function]







# Performance Guaranteed:

OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).